Popliteal artery stent Pulsar®-35

nitinolself-expanding

Indicated for use in patients with atherosclerotic disease of the femoral and proximal popliteal arteries, in particular for the treatment of insufficient results after Percutaneous Transluminal Angioplasty (PTA), e.g. residual stenosis and dissection.* Product Highlights 140 μm thin struts Clinically proven Tri-axial delivery system 140 μm thin struts Pulsar-35 struts are thinner than the leading brands.1 Thinner struts and lower COF make a difference:* • Lower risk of restenosis3 • Reduced vessel injury and inflammation3 • Faster endothelialization4,5 Clinically proven even in calcified lesions (4EVER), total occlusions (TASC D) and in all-comers registry (BIOFLEX PEACE).¤ ¤Clinical outcomes of Pulsar-18 can be used to illustrate clinical outcomes of Pulsar-35 due to identical stent platforms FTLR - Freedom from Target Lesion Revascularization; PP - Primary Patency; A.L.L. - Average Lesion Length Accurate stent deployment Tri-axial delivery system with ergonomic release handle One-handed stent release handle, ergonomically designed for a comfortable and stable handling. Tri-axial delivery system: the outer shaft isolates the retractable shaft from friction caused by the introducer valve to ensure accurate stent deployment. Technical Data Recommended guide wire - 0.035” Stent material - Nitinol Strut thickness - 140 μm Strut width - 85 μm Stent coating - proBIO® (Amorphous Silicon Carbide) Stent markers - 6 gold markers each end Proximal shaft - 6F, hydrophobic coating